Cargando…
Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs
A paper analytic device, the chemoPAD, was developed and validated to visually detect methotrexate, doxorubicin, cisplatin, and oxaliplatin at concentrations commonly found in injectable dosage forms. By testing residual solution after patient treatment, the chemoPAD can be used to monitor drug qual...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010420/ https://www.ncbi.nlm.nih.gov/pubmed/30589597 http://dx.doi.org/10.1200/JGO.18.00198 |
_version_ | 1783495874859499520 |
---|---|
author | Smith, Madeline Ashenef, Ayenew Lieberman, Marya |
author_facet | Smith, Madeline Ashenef, Ayenew Lieberman, Marya |
author_sort | Smith, Madeline |
collection | PubMed |
description | A paper analytic device, the chemoPAD, was developed and validated to visually detect methotrexate, doxorubicin, cisplatin, and oxaliplatin at concentrations commonly found in injectable dosage forms. By testing residual solution after patient treatment, the chemoPAD can be used to monitor drug quality without restriction of patient access to medication. The chemoPAD is produced by wax printing on Ahlstrom paper to create separate reaction areas and deposits small amounts of chemicals to create color changes in response to different active pharmaceutical ingredients (APIs). This creates a unique color bar code to identify each medication. Internal validation studies show that the chemoPAD has excellent sensitivity and specificity to differentiate between samples of 100% and 0% API, which is the distinction relevant to the majority of reported falsified chemotherapy cases. The platinum-containing drugs, cisplatin and oxaliplatin, can be detected semiquantitatively. The cards can be read either visually by comparison with a standard image or by using computer image analysis. Dosage forms were collected from the Ethiopian health care system and analyzed with the chemoPAD followed by high-performance liquid chromatography. A substandard sample was discovered and reported to the Ethiopian Food Medicine and Healthcare Administration and Control Authority. |
format | Online Article Text |
id | pubmed-7010420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-70104202020-02-12 Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs Smith, Madeline Ashenef, Ayenew Lieberman, Marya J Glob Oncol Original Reports A paper analytic device, the chemoPAD, was developed and validated to visually detect methotrexate, doxorubicin, cisplatin, and oxaliplatin at concentrations commonly found in injectable dosage forms. By testing residual solution after patient treatment, the chemoPAD can be used to monitor drug quality without restriction of patient access to medication. The chemoPAD is produced by wax printing on Ahlstrom paper to create separate reaction areas and deposits small amounts of chemicals to create color changes in response to different active pharmaceutical ingredients (APIs). This creates a unique color bar code to identify each medication. Internal validation studies show that the chemoPAD has excellent sensitivity and specificity to differentiate between samples of 100% and 0% API, which is the distinction relevant to the majority of reported falsified chemotherapy cases. The platinum-containing drugs, cisplatin and oxaliplatin, can be detected semiquantitatively. The cards can be read either visually by comparison with a standard image or by using computer image analysis. Dosage forms were collected from the Ethiopian health care system and analyzed with the chemoPAD followed by high-performance liquid chromatography. A substandard sample was discovered and reported to the Ethiopian Food Medicine and Healthcare Administration and Control Authority. American Society of Clinical Oncology 2018-12-27 /pmc/articles/PMC7010420/ /pubmed/30589597 http://dx.doi.org/10.1200/JGO.18.00198 Text en © 2018 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Reports Smith, Madeline Ashenef, Ayenew Lieberman, Marya Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs |
title | Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs |
title_full | Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs |
title_fullStr | Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs |
title_full_unstemmed | Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs |
title_short | Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs |
title_sort | paper analytic device to detect the presence of four chemotherapy drugs |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010420/ https://www.ncbi.nlm.nih.gov/pubmed/30589597 http://dx.doi.org/10.1200/JGO.18.00198 |
work_keys_str_mv | AT smithmadeline paperanalyticdevicetodetectthepresenceoffourchemotherapydrugs AT ashenefayenew paperanalyticdevicetodetectthepresenceoffourchemotherapydrugs AT liebermanmarya paperanalyticdevicetodetectthepresenceoffourchemotherapydrugs |